Several studies indicated that CD79A was connected with aggressive hematological malignancy, could be a popular marker in the detection and treatment of hematopathy such as Hodgkin’s lymphoma and B-cell lymphoma [29–31]. Here, CD79A is linked to Hodgkins lymphoma.